Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics Inc (NY: LCTX )

0.8158 -0.0155 (-1.86%)
Official Closing Price Updated: 8:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game?
Image by Rudy and Peter Skitterians from Pixabay Age-related macular degeneration (AMD) is a disease originating in the retina, which may worsen over time, according to... 
Via Benzinga
Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell's Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements
Lineage Cell Therapeutics Inc (NYSE: LCTX) reported updated interim results from its Phase 1/2a study of its lead product candidate, OpRegen cell therapy for dry... 
Via Benzinga
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Inks Option Agreement With Amasa Therapeutics For HyStem
Lineage Cell Therapeutics Inc (NYSE: LCTX) has granted an exclusive option to Amasa Therapeutics Inc to acquire an exclusive, royalty-bearing license to use its... 
Via Benzinga
Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem®
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen®
From Lineage Cell Therapeutics, Inc.
Via Business Wire
68 Biggest Movers From Yesterday
Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares surged 115.2% to close at $7.64 on Tuesday after the company announced its subsidiary, Gibson Technical Services, reached... 
Via Benzinga
Why Lineage Cell Therapeutics Stock Is Soaring Today
The company reported great news from a clinical study of its experimental cell therapy for treating eye disease. 
Via The Motley Fool
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares jumped 67.3% to $5.94 after the company announced its subsidiary, Gibson Technical Services, reached an agreement with TEC... 
Via Benzinga
Lineage Cell Stock Jumps as OpRegen Shows Additional Cases Of Retinal Tissue Restoration In Mid-Stage Study
Lineage Cell Therapeutics Inc (NYSE: LCTX) has announced that restoration of retinal tissue was observed in two additional patients enrolled in the Phase 1/2a... 
Via Benzinga
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2021 Earnings Call Transcript
LCTX earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors
From Lineage Cell Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell's Dry Age-Related Macular Degeneration Cell Therapy Associated With Stable Or Improved Vision
Lineage Cell Therapeutics Inc (NYSE: LCTX) has updated interim results from its ongoing Phase 1/2a study of its lead product candidate, OpRegen, for dry age-... 
Via Benzinga
OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.